Bivalirudin labels and packages: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Bivalirudin}} {{CMG}} {{AE}}{{JH}} ==Title== <ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTIO...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{JH}} | {{CMG}} {{AE}}{{JH}} | ||
== | ==Labels and Packeges== | ||
PRINCIPAL DISPLAY PANEL | |||
NDC 65293-001-01 | |||
<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref> | Angiomax® | ||
(bivalirudin) | |||
FOR INJECTION | |||
250 mg | |||
For Intravenous Use Only | |||
Rx Only | |||
10 Single Use Vials<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
{| | |||
| [[File:Bivalirudin_10.png|thumb|600px]] | |||
|} | |||
{| | |||
| [[File:Bivalirudin_11.png|thumb|600px]] | |||
|} | |||
{| | |||
| [[File:Bivalirudin_12.png|thumb|600px]] | |||
|} | |||
==References== | ==References== | ||
Revision as of 18:37, 10 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Labels and Packeges
PRINCIPAL DISPLAY PANEL
NDC 65293-001-01
Angiomax® (bivalirudin) FOR INJECTION
250 mg
For Intravenous Use Only Rx Only
10 Single Use Vials[1]
 |
 |
 |
References
- ↑ "ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY]". Retrieved 10 March 2014.
Adapted from the FDA Package Insert.